Background AKAP12/Gravin (A kinase anchor protein 12) is one of the A-kinase scaffold proteins and a potential tumor suppressor gene in human primary cancers. Our recent study demonstrated the highly recurrent loss of AKAP12 in colorectal cancer and AKAP12 reexpression inhibited proliferation and anchorage-independent growth in colorectal cancer cells, implicating AKAP12 in colorectal cancer pathogenesis. Methods To evaluate the effect of this gene on the progression and metastasis of colorectal cancer, we examined the impact of overexpressing AKAP12 in the AKAP12-negative human colorectal cancer cell line LoVo, the single clone (LoVo-AKAP12) compared to mock-transfected cells (LoVo-CON). Results pCMV6-AKAP12-mediated AKAP12 re-expression induced apoptosis (3% to 12.7%, p<0.01), migration (89.6±7.5 cells to 31.0±4.1 cells, p<0.01) and invasion (82.7±5.2 cells to 24.7±3.3 cells, p<0.01) of LoVo cells in vitro compared to control cells. Nude mice injected with LoVo-AKAP12 cells had both significantly reduced tumor volume (p<0.01) and increased apoptosis compared to mice given AKAP12-CON. The quantitative human-specific Alu PCR analysis showed overexpression of AKAP12 suppressed the number of intravasated cells in vivo (p<0.01). Conclusion These results demonstrate that AKAP12 may play an important role in tumor growth suppression and the survival of human colorectal cancer.
References
[1]
Wallner M, Herbst A, Behrens A, Crispin A, Stieber P, et al. (2006) Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res 12: 7347–7352.
[2]
Agrawal A, Murphy RF, Agrawal DK (2007) DNA methylation in breast and colorectal cancers. Mod Pathol 20: 711–721.
[3]
Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics 2007. CA Cancer J Clin 57: 43–66.
[4]
Gordon T, Grove B, Loftus JC, O'Toole T, McMillan R, et al. (1992) Molecular cloning and preliminary characterization of a novel cytoplasmic antigen recognized by myasthenia gravis sera. J Clin Invest 90: 992–999.
[5]
Nauert JB, Klauck TM, Langeberg LK, Scott JD (1997) Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. Curr Biol 7: 52–62.
[6]
Tessema M, Willink R, Do K, Yu YY, Yu W, et al. (2008) Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. Cancer Res 68: 1707–1714.
[7]
Wang HY, Tao J, Shumay E, Malbon CC (2006) G-Protein-coupled receptor-associated A-kinase anchoring proteins: AKAP79 and AKAP250 (gravin). Eur J Cell Biol 85: 643–650.
[8]
Choi MC, Jong HS, Kim TY, Song SH, Lee DS, et al. (2004) AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene 23: 7095–7103.
[9]
Jin Z, Hamilton JP, Yang J, Mori Y, Olaru A, et al. (2008) Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression. Cancer Epidemiol Biomarkers Prev 17: 111–117.
[10]
Flotho C, Paulun A, Batz C, Niemeyer CM (2007) AKAP12, a gene with tumour suppressor properties, is a target of promoter DNA methylation in childhood myeloid malignancies. Br J Haematol 138: 644–650.
[11]
Heller G, Schmidt WM, Ziegler B, Holzer S, Mullauer L, et al. (2008) Genome-wide transcriptional response to 5-aza-2′-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res 68: 44–54.
[12]
Mori Y, Cai K, Cheng Y, Wang S, Paun B, et al. (2006) A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology 131: 797–808.
[13]
Liu W, Guan M, Su B, Ye C, Li J, et al. (2010) Quantitative assessment of AKAP12 promoter methylation in colorectal cancer using methylation-sensitive high resolution melting: Correlation with dukes' stage. Cancer Biol Ther 9: 862–871.
[14]
Lowe SW, Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21: 485–495.
S progression by controlling the expression and cellular compartmentalization of cyclin D. Mol Cell Biol 20: 7259–7272. -->
[15]
Lin X, Nelson P, Gelman IH (2000) SSeCKS, a major protein kinase C substrate with tumor suppressor activity, regulates G(1)-->S progression by controlling the expression and cellular compartmentalization of cyclin D. Mol Cell Biol 20: 7259–7272.
[16]
Lin X, Gelman IH (1997) Reexpression of the major protein kinase C substrate, SSeCKS, suppresses v-src-induced morphological transformation and tumorigenesis. Cancer Res 57: 2304–2312.
[17]
Xia W, Unger P, Miller L, Nelson J, Gelman IH (2001) The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res 61: 5644–5651.
[18]
Yoon DK, Jeong CH, Jun HO, Chun KH, Cha JH, et al. (2007) AKAP12 induces apoptotic cell death in human fibrosarcoma cells by regulating CDKI-cyclin D1 and caspase-3 activity. Cancer Lett 254: 111–118.
[19]
Liu Y, Gao L, Gelman IH (2006) SSeCKS/Gravin/AKAP12 attenuates expression of proliferative and angiogenic genes during suppression of v-Src-induced oncogenesis. BMC Cancer 6: 105.
[20]
Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124: 619–626.
[21]
Liotta LA, Kohn E (2004) Anoikis: cancer and the homeless cell. Nature 430: 973–974.
[22]
Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, et al. (2009) Effects of Raf Kinase Inhibitor Protein Expression on Metastasis and Progression of Human Breast Cancer. Mol Cancer Res 7: 832–840.
[23]
Su B, Zheng Q, Vaughan MM, Bu Y, Gelman IH (2006) SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition. Cancer Res 66: 5599–5607.
[24]
Su B, Bu Y, Engelberg D, Gelman IH (2009) SSeCKS/Gravin/AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a PKC-RAF/MEK/ERK pathway. J Biol Chem 285: 4578–4586.
[25]
Weiser DC, Pyati UJ, Kimelman D (2007) Gravin regulates mesodermal cell behavior changes required for axis elongation during zebrafish gastrulation. Genes Dev 21: 1559–1571.
[26]
Guan M, Yam HF, Su B, Chan KP, Pang CP, et al. (2003) Loss of pigment epithelium derived factor expression in glioma progression. J Clin Pathol 56: 277–282.
[27]
Li J, Huang H, Sun L, Yang M, Pan C, et al. (2009) MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 15: 3998–4008.
[28]
Lee WJ, Chen WK, Wang CJ, Lin WL, Tseng TH (2008) Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol 226: 178–191.
